Type of information: Development agreement
Compound: rAAVrh10 vectors
Company: Lysogene (France) Regenx Biosciences (USA - MD)
Therapeutic area: Rare diseases
Type agreement: development
Disease: mucopolysaccharidosis type IIIA (MPS IIIA or Sanfilippo syndrome Type A)
Under the terms of the agreement, Regenx granted Lysogene an exclusive worldwide license, with rights to sublicense, to Regenx\'s NAV rAAVrh10 vectors for treatment of MPS IIIA in humans. In return for these rights, Regenx receives payments in the form of an up-front payment, certain milestone fees and royalties on net sales of products incorporating NAV rAAVrh10.